ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; citric acid monohydrate; microcrystalline cellulose; magnesium stearate; poloxamer; calcium hydrogen phosphate dihydrate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - raloxifene generichealth is proposed to be used for:,1. the prevention and treatment of osteoprosis in post-menopausal women,2. the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis,3. the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer,high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

माल्टा - अंग्रेज़ी - Medicines Authority

bristol laboratories limited - raloxifene hydrochloride - film-coated tablet - raloxifene hydrochloride 60 milligram(s) - sex hormones and modulators of the genital system

माल्टा - अंग्रेज़ी - Medicines Authority

brillpharma (ireland) limited inniscarra, main street, rathcoole, co. dublin, ireland - raloxifene hydrochloride - film-coated tablet - raloxifene hydrochloride 60 mg - sex hormones and modulators of the genital system

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

a-s medication solutions - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] .  raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperpl

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

avera mckennan hospital - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

actavis pharma, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; crospovidone; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 400; povidone - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; povidone; microcrystalline cellulose; crospovidone; citric acid monohydrate; polysorbate 80; titanium dioxide; magnesium stearate - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; polysorbate 80; povidone; microcrystalline cellulose; magnesium stearate; glycine; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - raloxifene hydrochloride -